Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Herzuma + gedatolisib
- Development stage
- Unknown
- Lead developer
- Celcuity
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Herzuma + gedatolisib is a combination therapy consisting of Herzuma (a trastuzumab biosimilar) and gedatolisib (a dual PI3K/mTOR inhibitor). This combination targets HER2-positive metastatic breast cancer, particularly in patients with PIK3CA aberrations who have progressed after multiple lines of HER2-directed therapies. Herzuma binds to the HER2/neu receptor, reducing HER2 expression and inhibiting tumor-supporting blood vessel growth. Gedatolisib targets the mTOR/PI3K signaling pathway, which plays a crucial role in tumor growth and proliferation. The combination has shown promising results in clinical trials, with an overall response rate of 58.8% and a disease control rate of 82.4% in patients with HER2-positive metastatic breast cancer with PIK3CA aberrations.
- Brand names
- Herzuma
- Other names
- Trastuzumab biosimilar plus gedatolisib
02
Targets
PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)ERBB2 (Erb-b2 receptor tyrosine kinase 2)PIK3CA (Phosphoinositide 3-kinase alpha)mTOR (Mammalian target of rapamycin kinase)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)
Beyond the preview
Go deeper on Herzuma + gedatolisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Herzuma + gedatolisib.